Hepatitis B vaccination in high-risk infants: 10-year follow-up

Journal of Infectious Diseases

Volumn 179, Issue 6, 1999, Pages 1319-1325

  Wu, Judy S ^b   Hwang, Lu Yu ^a   Goodman, Karen J ^b   Beasley, R Palmer ^b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN;

ANTIBODY DETECTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; LONG TERM CARE; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TAIWAN; VACCINATION;

CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION, VERTICAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; INCIDENCE; INFANT; MALE; MULTIVARIATE ANALYSIS; RISK; TAIWAN; VACCINATION;

EID: 0033023108     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314768     Document Type: Article

References (42)

1. 1. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995;13(suppl 1):S47-9.
2. 2. Van Damme P, Tormans G, Beutels P, Van Doorslaer E. Hepatitis B prevention in Europe: a preliminary economic evaluation. Vaccine 1995;13(suppl 1):S54-7.
3. 3. Ding L, Zhang M, Wang Y, Zhou S, Kong W, Smego RA Jr. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin Infect Dis 1993; 17:475-9.
4. 4. Xu ZY, Duan SC, Margolis HS, et al. Long-term efficacy of active post-exposure immunization of infants for prevention of hepatitis B virus infection. J Infect Dis 1995;171:54-60.
5. 5. Steven CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292:771-4.
6. 6. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977;105: 94-8.
7. 7. Lo KJ, Lee SD, Tsai YT. Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan. Hepatogastroenterology 1985;32:65-8.
8. 8. Lo KJ, Lee SD, Tsai YT, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in infants born to HBcAg-positive HBsAg-carrier mothers. Hepatology 1988;8:1647-50.
9. 9. Marion SA, Pastore MT, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol 1994;140: 734-46.
10. 10. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2:1099-102.
11. 11. Stevens CE, Toy PT, Taylor PE, Lee T, Yip HY. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Pediatrics 1992;90:170-3.
12. 12. Coursaget P, Chotard J, Vincelot P, et al. Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet 1986; 2:1143-5.
13. 13. Resti M, Azzari C, Rossi ME, Adami Lami C, Tucci F, Vierucci A. Five-year follow-up of vaccination against hepatitis B virus in newborns vaccinated with a reduced number of doses. Vaccine 1991;9:15-8.
14. 14. Delage G, Rémy-Prince S, Montplaisir S. Combined active-passive immunization against the hepatitis B virus: five-year follow-up of children born to hepatitis B surface antigen positive mothers. Pediatr Infect Dis J 1993;12:126-30.
15. 15. Poovorawan Y, Sanpavat S, Pongpunglert W, et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 1992;11:816-21.
16. 16. Farmer K, Gunn T, Woodfield DG. A combination of hepatitis B vaccine and immunoglobulin does not protect all infants born to hepatitis B e antigen positive mothers. N Z Med J 1987;100:412-4.
17. 17. Wainwright RB, McMahon BJ, Bulkw LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989;261:2362-6.
18. 18. Mahoney FJ, Woodruff BA, Erben JJ, et al. Effect of a hepatitis B vaccination program on the prevalence of hepatitis B virus infection. J Infect Dis 1993;167:203-7.
19. 19. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315:209-14.
20. 20. Berger R, Just M, André F, Safary A. Boosting against hepatitis B: must it be done when titers disappear? In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Alan R. Liss, 1988:1006-8.
21. 21. Chotard J, Inskip HM, Hall AJ, et al. The Gambia hepatitis intervention study: follow-up of a cohort of children vaccinated against hepatitis B. J Infect Dis 1992;166:764-8.
22. 22. Gibas A, Watkins E, Hinkle C, Dienstag JL. Long-term persistence of protective antibody after hepatitis vaccination of healthy adults. In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Alan R. Liss, 1988:998-1001.
23. 23. Couroucé AM, Laplanche A, Benhamou E, Jungers P. Long-term efficacy of hepatitis B vaccination in healthy adults. In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Alan R. Liss, 1988:1002-5.
24. 24. Lee GC, Hwang LY, Beasley RP, Chen SH, Lee TY. Immunogenicity of hepatitis B virus vaccine in healthy Chinese neonates. J Infect Dis 1983;148:526-9.
25. 25. Hwang LY, Lee CY, Beasley RP. Five-year follow-up of HBV vaccination with plasma-derived vaccine in neonates: evaluation of immunogenicity and efficacy against perinatal transmission. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral hepatitis and liver disease: proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: Contemporary Issues and Future Prospects. Baltimore: Williams & Wilkins, 1990: 759-61.
26. 26. Lee CY, Hwang LY, Beasley RP. Low-dose hepatitis B vaccine. Lancet 1989; 2:860-1.
27. 27. Centers for Disease Control, Protection against viral hepatitis. MMWR Morb Mortal Wkly Rep 1990;39(RR-2):1-26.
28. 28. Centers for Disease Conrol. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR Morb Mortal Wkly Rep 1991;40(RR-13):1-25.
29. 29. Jilg W, Schmidt F, Deinhardt F. Four-year experience with a recombinant hepatitis B vaccine. Infection 1989;17:70-6.
30. 30. Jilg W, Lorbeer B, Schmidt M, Wilske B, Zoulek G, Deinhardt F. Clinical evaluation of a recombinant hepatitis B vaccine. Lancet 1984;2:1174-5.
31. 31. Scheiermann N, Gesemann KM, Paar D, Maurer C. Reactogenicity and immunogenicity of a new recombinant yeast-derived hepatitis B vaccine. Zentralbl Bakteriol Mikrobiol Hyg [A] 1988;269:411-21.
32. 32. Zhu QR, Gu XH, Duan SC, Xu HF. Long-term immunogenicity and efficacy of recombinant yeast derived hepatitis B vaccine for interruption of mother-infant transmission of hepatitis B virus. Chin Med J (Engl) 1994;107:915-8.
33. 33. Da Villa G, Peluso F, Picciotto L, Bencivenga M, Elia S, Pelliccia MG. Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years. Vaccine 1996;14:1503-5.
34. 34. Hayashi J, Kashiwagi S, Kajiyama W, et al. Comparison of results of recombinant and plasma-derived hepatitis B vaccines in Japanese nursery-school children. J Infect 1988;17:49-55.
35. 35. Bland J, Clements J. Protecting the world's children: the story of WHO'S immunization programme. World Health Forum 1998;19:162-173.
36. 36. Taylor PE, Stevens CE. Persistence of antibody to hepatitis B surface antigen after vaccination with hepatitis B vaccine. In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Alan R. Liss, 1988:995-7.
37. 37. Gesemann M, Scheiermann N. Quantification of hepatitis B vaccine induced antibodies as a predictor of anti-HBs persistence. Vaccine 1995;13:443-7.
38. 38. Martin P, Friedman LS, Dienstag JL. Diagnostic approach. In: Zuckerman AJ, Thomas HC, eds. Viral hepatitis: scientific basis and clinical management. Edinburgh: Churchill Livingstone, 1993: 394-409.
39. 39. Hadler SC. Are booster doses of hepatitis B vaccine necessary? Ann Intern Med 1988;108:457-8.
40. 40. Resti M, Di Francesco G, Azzari C, Rossi ME, Vierucci A. Anti-HBs and immunological memory to HBV vaccine: implication for booster timing. Vaccine 1993;11:1079.
41. 41. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.
42. 42. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc R Soc Lond B Biol Sci 1993;253:197-201.